California Attorney General Xavier Becerra said that Teva illegally maintained a monopoly over the sales of narcolepsy drug Provigil by entering into “pay-for-delay” agreements with the brandname drugmaker. Under the agreement, Teva delayed the entry of its generic by almost six years.
While pay-for-delay agreements are not illegal, they can be used in ways that violate antitrust law, according to the report.
As part of the settlement, Teva will pay $69 million to the state. A portion of the settlement will be paid to California residents who purchased Provigil from 2006 to 2012. Additionally, Teva is under a 10-year injection that prevents it from entering into pay-for-delay deals.
At the same time, Teva, Endo and Teikoku Pharma allegedly struck pay-for-delay deals for Lidoderm, a medical patch to treat shingles pain, which delayed generics for almost two years. Under that settlement, Endo will pay $760,000 to the state of California and will enter an eight-year injunction preventing it from entering pay-for-delay agreements. Teikoku will be under a 20-year injunction.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Clinics leaving family planning program may have to toss thousands of dollars worth of drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
